Gastrointestinal stromal tumor surgery: Difference between revisions
Jump to navigation
Jump to search
Akshun Kalia (talk | contribs) No edit summary |
Akshun Kalia (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}}{{AE}}{{PSD}} | {{CMG}}{{AE}}{{PSD}} | ||
{{Gastrointestinal stromal tumor}} | {{Gastrointestinal stromal tumor}} | ||
| Line 6: | Line 7: | ||
==Surgical Therapy== | ==Surgical Therapy== | ||
Surgery is typically the initial therapy for the | Surgery is the definitive therapy and typically the initial therapy for patients of GIST. | ||
* | *Surgical resection offers an opportunity to completely cure GIST. | ||
* | *Laparoscopic resection is the most preferred route of surgery. The indications for surgery include: | ||
**Symptomatic patients with locally advanced or metastatic disease. | |||
**Large lesions and tumors that are technically resectable if the risks of morbidity are acceptable | |||
* Surgical resection of GIST include complete gross resection with with an intact pseudocapsule and negative microscopic margins. | |||
* In GIST, lymph node metastasis is rare and therefore lymphadenectomy of clinically uninvolved nodes is not necessary. | |||
* Most small GISTs (<5 and especially <2 cm) with a low rate of [[mitosis]] (<5 dividing cells per 50 high-power fields) are [[benign]] and, after surgery, do not require [[adjuvant therapy]]. | * Most small GISTs (<5 and especially <2 cm) with a low rate of [[mitosis]] (<5 dividing cells per 50 high-power fields) are [[benign]] and, after surgery, do not require [[adjuvant therapy]]. | ||
| Line 18: | Line 22: | ||
* Until recently, GISTs were notorious for being resistant to [[chemotherapy]], with a success rate of <5%. Recently, the ''c-kit'' [[tyrosine kinase]] inhibitor [[imatinib]], a drug initially marketed for [[chronic myelogenous leukemia]], was found to be useful in treating GISTs, leading to a 40-70% response rate in metastatic or inoperable cases.<ref>{{Cite web | title =Gastrointestinal Stromal Tumors Treatment | * Until recently, GISTs were notorious for being resistant to [[chemotherapy]], with a success rate of <5%. Recently, the ''c-kit'' [[tyrosine kinase]] inhibitor [[imatinib]], a drug initially marketed for [[chronic myelogenous leukemia]], was found to be useful in treating GISTs, leading to a 40-70% response rate in metastatic or inoperable cases.<ref>{{Cite web | title =Gastrointestinal Stromal Tumors Treatment | ||
| url =http://www.cancer.gov/types/soft-tissue-sarcoma/hp/gist-treatment-pdq#section/_35}}</ref> | | url =http://www.cancer.gov/types/soft-tissue-sarcoma/hp/gist-treatment-pdq#section/_35}}</ref> | ||
Revision as of 20:53, 12 December 2017
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
|
Gastrointestinal stromal tumor Microchapters |
|
Differentiating Gastrointestinal stromal tumor from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Gastrointestinal stromal tumor surgery On the Web |
|
American Roentgen Ray Society Images of Gastrointestinal stromal tumor surgery |
|
Directions to Hospitals Treating Gastrointestinal stromal tumor |
|
Risk calculators and risk factors for Gastrointestinal stromal tumor surgery |
Overview
The predominant therapy for gastrointestinal stromal tumor is surgical resection. Adjunctive chemotherapy/tyrosine Kinase Inhibitor therapy may be required.
Surgical Therapy
Surgery is the definitive therapy and typically the initial therapy for patients of GIST.
- Surgical resection offers an opportunity to completely cure GIST.
- Laparoscopic resection is the most preferred route of surgery. The indications for surgery include:
- Symptomatic patients with locally advanced or metastatic disease.
- Large lesions and tumors that are technically resectable if the risks of morbidity are acceptable
- Surgical resection of GIST include complete gross resection with with an intact pseudocapsule and negative microscopic margins.
- In GIST, lymph node metastasis is rare and therefore lymphadenectomy of clinically uninvolved nodes is not necessary.
- Most small GISTs (<5 and especially <2 cm) with a low rate of mitosis (<5 dividing cells per 50 high-power fields) are benign and, after surgery, do not require adjuvant therapy.
- Larger GISTs (>5 cm), and especially when the cell division rate is high (>6 mitoses/50 HPF), may disseminate and/or recur.
- Until recently, GISTs were notorious for being resistant to chemotherapy, with a success rate of <5%. Recently, the c-kit tyrosine kinase inhibitor imatinib, a drug initially marketed for chronic myelogenous leukemia, was found to be useful in treating GISTs, leading to a 40-70% response rate in metastatic or inoperable cases.[1]
References